Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
DNAtrix, Inc.
With
H. Lee Moffitt Cancer Center and Research Institute
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female aged ≥ 18 years at time of consent
Diagnosis of liver metastases from colorectal, breast, gastric, periampullary, melanoma, renal cell cancer, sarcoma, squamous cell carcinoma or gastrointestinal stromal tumor
Multiple (≥ 2) liver tumors
Candidate for curative-intent surgery
Stated willingness to comply with all study procedures and availability for the duration of the study.
Candidates eligible for targeted therapy, as per standard of care guidelines (and based on mutational status as indicated), must have completed therapy
Preoperative chemotherapy is allowed
You may not be if
Recurrence of liver metastasis
Diagnosis of neuroendocrine tumor liver metastasis
Liver metastasis treated with \> 12 cycles of systemic chemotherapy
Condition that requires ongoing systemic immunosuppressive therapy
Evidence of inadequate organ function based on lab parameters
Liver transaminases (aspartate aminotransferase \[AST\] and/or alanine aminotransferase \[ALT\]) or total bilirubin \> 5x the upper limits of normal
Males or females who refuse to use a double-barrier form of birth control during the study and for up to 6 months after injection with DNX-2440
Clareo Health | DNX-2440 for Resectable Colorectal Liver Metastasis
